Naproxen Label Shows Limitations Of Class Effect Thinking – Harvard’s Avorn
This article was originally published in The Tan Sheet
Executive Summary
The inclusion of naproxen in NSAID cardiovascular warning label requirements is an overextension of the use of "class effect" labeling, pharmacoepidemiologist Jerry Avorn, Harvard University, said